Variability is correlated with increasing repeat length, increasing purity, and decreasing unit size. by John W. Fondon III (145820)

Mutation of Ser-473 in GC-A to alanine but not glutamate decreases ANP-stimulated guanylyl cyclase activity. by Andrea R. Yoder (165684)

Fluorescence intensity curves of <i>M</i>. <i>aeruginosa</i> after H₂O₂ and light treatments from UV, violet, blue, yellow-green, red laser excitation. by Emma T. Brentjens (17295999)

Subjects:

Time-resolved EELS spectra, as a function of decreasing water vapor pressure. by Cathal Cassidy (1758703)

Structure of YOLOv5s-SBC. by Zhongjian Xie (4633099)

“…Compared to the original model, P-YOLOv5s-GRNF decreased parameters by 18%, decreased model size to 11.9MB, decreased FLOPs to 14.5G, and increased FPS by 4.3. …”

Acetylcholine-induced NO- and EDHF-mediated relaxations decrease with increasing age. by Noureddine Idris Khodja (331400)

Decrease of actin velocity when passing confined TCR clusters. by Cheng-han Yu (244912)

Fluoxetine decreases TOPFlash firefly luciferase reporter activity. by Kentaro Miyamoto (123271)

Early increase and later decrease in GSK-3β activity. by Arie J. Hoogendijk (353624)

Conventional dynamic latch comparator [13], [14]. by Labonnah Farzana Rahman (641767)

Subjects:

Chronic, sublethal neonicotinoid exposure decreases cumulative weight gain and cluster size of honey bee colonies. by Sarah C. Wood (4730634)

Performance comparison of the proposed dynamic latch comparator. by Labonnah Farzana Rahman (641767)

Subjects:

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Subjects:

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects: